OVs can be “armed” with transgenes expressing immunostimulatory cytokines and chemokines (e.g., T-VEC expresses GM-CSF) or can release some other costimulatory ligands that support tumor-specific T cell expansion and activation inside and outside the tumor site [18]. The gene discussed is CSF2; the disease is neoplasm.